Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Rationale for Investigating AIs for Premenopausal<br />
Endocrine-Responsive Breast Cancer<br />
• Aromatase inhibitors (AIs) have superior efficacy<br />
compared with tamoxifen for postmenopausal<br />
endocrine-responsive breast cancer 1-7<br />
– Significantly prolong disease-free survival (DFS)<br />
– Significantly reduce distant recurrence<br />
• ANA plus goserelin significantly reduced mean<br />
estrogen levels in premenopausal women who<br />
experienced disease progression during treatment<br />
with goserelin plus TAM (P < .0001) 8<br />
– TAM + goserelin reduced estrogen by 89%<br />
– ANA + goserelin further reduced estrogen by an additional 76%<br />
ANA = Anastrozole; TAM = Tamoxifen.<br />
1. Howell A, et al. Lancet. 2005;365:60-62; 2. Thurlimann B, et al. N Engl J Med. 2005;353:2747-2757; 3. Coates A, et al. J Clin<br />
Oncol. 2007;25:486-492; 4. Coombes RC, et al. N Engl J Med. 2004;350:1<strong>08</strong>1-1092; 5. Coombes RC, et al. Lancet.<br />
2007;369:559-570; 6. Jakesz R, et al. Lancet. 2005;366:455-462; 7. Goss P, et al. J Natl Cancer Inst. 2005;97:1262-1271;<br />
8. Forward DP, et al. Br J Cancer. 2004;90:590-594.<br />
3
Change language